Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Design and experimental evaluation of a minimal, innocuous watermarking strategy to distinguish near-identical DNA and RNA sequences

ABSTRACT: F. Boonekamp et al., (2019) describe an innocuous watermarking strategy for coding regions that enables the discrimination of DNA and mRNA by sequencing through a k-mer approach and facilitates selective editing of watermarked and non-watermarked sequences. Shot-gun proteomics (LFQ) was performed on the parent and the engineered yeast strain. *Corresponding author: Pascale Daran-Lapujade (p.a.s.daran-lapujade@tudelft.nl). Department of Biotechnology, Delft University of Technology, van der Maasweg 9, 2629HZ Delft, The Netherlands

INSTRUMENT(S): Q Exactive

ORGANISM(S): Saccharomyces Cerevisiae (baker's Yeast)

SUBMITTER: Martin Pabst

LAB HEAD: Martin Pabst

PROVIDER: PXD016914 | Pride | 2020-09-21

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Similar Datasets

Anammox enrichment culture glycoproteomics

Project description:The physiology of the planctomycetal anammox bacteria makes them particularly special because they share features with all three domains of life. Anammox bacteria have been reported recently to produce surface-layer proteins, which represent the outermost layer and provide structure, shape and protection under extreme conditions. Furthermore, we report on the unique cell surface-layer glycosylation of the anammox bacterium Ca. Kuenenia stuttgartiensis as revealed by a newly established glycoproteomics approach. This approach enables untargeted exploration of prokaryotic protein glycosylation from (high-resolution) shotgun proteomics data directly.

2021-08-05 | PXD021600 | Pride

Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom

Project description:Primary objectives: Primäres Studienziel der Phase IDefinition der empfohlenen Dosis von Capecitabin und Oxaliplatin bei gleichzeitiger Therapie mit Bevacizumab und Imatinib. Primäres Studienziel der Phase IIMachbarkeit und Verträglichkeit der in der Phase I ermittelten Dosis der Kombination aus XELOX mit Bevacizumab und Imatinib anhand der Bestimmung der Sicherheit und der Nebenwirkungen und Toxizitäten der Kombinationstherapie. Primary endpoints: Phase I Definition der empfohlenen Dosis von Capecitabin und Oxaliplatin bei gleichzeitiger Therapie mit Imatinib und Bevacizumab. Phase II Bestimmung der Sicherheit und der Nebenwirkungen und Toxizitäten der Kombinationstherapie mit Capecitabin, Oxaliplatin, Imatinib und Bevacizumab

| 2521499 | ecrin-mdr-crc

Shot-gun proteomic analysis of S Cerevisiae, Candidatus Accumulibacter and Clostridium sacch.

Project description:Shot-gun whole cell lysate proteomics data from pure and enriched microbes were de-novo sequenced using PEAKS de Novo. The obtained peptide sequence lists serves as a test data for the peptide-centric taxonomy database Unipept.

2021-03-15 | PXD016992 | Pride

Biomarkers of dietary energy restriction in women at increased risk of breast cancer

Project description:Dietary energy restriction (DER) reduces risk of spontaneous mammary cancer in rodents. In humans, DER in premenopausal years seems to reduce risk of postmenopausal breast cancer. Markers of DER are required to develop acceptable DER regimens for breast cancer prevention. We therefore examined markers of DER in the breast, adipose tissue, and serum. Nineteen overweight or obese women at moderately increased risk of breast cancer (lifetime risk, 1 in 6 to 1 in 3) ages between 35 and 45 were randomly allocated to DER [liquid diet, 3,656 kJ/d (864 kcal/d); n = 10] or asked to continue their normal eating patterns (n = 9) for one menstrual cycle. Biopsies of the breast and abdominal fat were taken before and after the intervention. RNA was extracted from whole tissues and breast epithelium (by laser capture microdissection) and hybridized to Affymetrix GeneChips. Longitudinal plasma and urine samples were collected before and after intervention, and metabolic profiles were generated using gas chromatography-mass spectrometry. DER was associated with significant reductions in weight [-7.0 (+/-2.3) kg] and in alterations of serum biomarkers of breast cancer risk (insulin, leptin, total and low-density lipoprotein cholesterol, and triglycerides). In both abdominal and breast tissues, as well as isolated breast epithelial cells, genes involved in glycolytic and lipid synthesis pathways (including stearoyl-CoA desaturase, fatty acid desaturase, and aldolase C) were significantly down-regulated. We conclude that reduced expressions of genes in the lipid metabolism and glycolytic pathways are detectable in breast tissue following DER, and these may represent targets for DER mimetics as effective chemoprophylactic agents Transcriptomic and Metabolomic intervention study of continuous energy restriction in 19 participants

2016-07-13 | GSE66159 | GEO

Design and Experimental Evaluation of a Minimal, Innocuous Watermarking Strategy to Distinguish Near-Identical DNA and RNA Sequences.

Project description: Not available

| S-EPMC7309318 | biostudies-literature

Expression data from MDS patients with der(1;7)(q10;p10)

Project description:Gene expression profiling was significantly different between der(1;7)(q10;p10) and -7/7q- patients by cluster analysis. There were total 1628 dysregulated genes in both der(1;7)(q10;p10) and -7/del(7q) cohorts.

2017-09-22 | GSE100340 | GEO

Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom

Project description:Primary objectives: Progressionsfreie Rate (PFS-Rate) nach 9 Monaten, definiert ab Tag des Therapiebeginns bis zum ersten Auftreten irgendeines der folgenden Ereignisse: Diagnose einer Progression der Erkrankung, eines Zweitmalignoms oder Tod jedweder Ursache Primary endpoints: Es handelt sich um eine Phase II-Studie, mit der die Effektivität einer innovativen Chemo/Immuntherapie-Kombination, bestehend aus Capecitabin und Bevacizumab im Hinblick auf eine zukünftige Erprobung im Rahmen einer umfangreichen Phase III-Studie abgeschätzt werden soll. Als primäres Zielkriterium dient hierbei die progressionsfreie Rate (PFS-Rate) nach 9 Monaten. Diesem Endpunkt wird der Vorzug gegenüber der objektiven Remissionsrate gegeben, da die bisherigen Erfahrungen mit den neuen Wirkstoffen dafür sprechen, dass ihr Potential sich in stärkerem Maße bei der Verzögerung einer Progression bzw. sogar Überlebensverlängerung auswirkt als bei der kurzfristigen Induktion deutlicher Tumorrückbildungen.

| 2517518 | ecrin-mdr-crc

Design and experimental evaluation of a minimal, innocuous watermarking strategy to distinguish near-identical DNA and RNA sequences

Project description:The construction of powerful cell factories requires intensive and extensive remodelling of microbial genomes. Considering the rapidly increasing number of these synthetic biology endeavours, there is an increasing need for DNA watermarking strategies that enable the discrimination between synthetic and native gene copies. While it is well documented that codon usage can affect translation, and most likely mRNA stability in eukaryotes, remarkably few quantitative studies explore the impact of watermarking on transcription, protein expression and physiology in the popular model and industrial yeast Saccharomyces cerevisiae. The present study, using S. cerevisiae as eukaryotic paradigm, designed, implemented and experimentally validated a systematic strategy to watermark DNA with minimal alteration of yeast physiology. The thirteen genes encoding proteins involved in the major pathway for sugar utilization (i.e glycolysis and alcoholic fermentation) were simultaneously watermarked in a yeast strain using the previously published pathway swapping strategy. Carefully swapping codons of these naturally codon optimized, highly expressed genes, did not alter transcript abundance, protein activity and yeast physiology. The markerQuant bioinformatics method could reliably discriminate native from watermarked genes and transcripts. Furthermore, presence of watermarks enabled selective CRISPR/Cas genome editing, specifically targeting the native gene copy while leaving the synthetic, watermarked variant intact. This study offers a validated strategy to simply watermark genes in S. cerevisiae.

2020-06-29 | GSE135470 | GEO

Strain-dependent Dissociation of Airway Hyper-responsiveness from Inflammation in a House Dust Mite Model of Asthma

Project description:Gene expression analysis of Der p 1-treated mouse lungs. We developed a new mouse model of allergic airway disease employing the house dust mite allergen Der p 1. This model produces qualitatively and quantitatively different effects in two commonly used inbred strains of mice, C57BL/6J and BALB/cJ, demonstrating that genetic background is an important determinant of response to Der p 1. To identify the genes and pathways associated with inflammation and pathophysiology, we used microarrays and found genes that were shared by both strains or were distinct. Among the latter, we identified three G-protein coupled receptors and a number of other genes and pathways whose expression patterns clearly distinguish the divergent physiologic responses of the two strains. We conclude that genetic background is a strong determinant of the type and intensity of response to Der p 1, including the degree of airway hyper-responsiveness and/or inflammation.

2010-11-30 | GSE19223 | GEO

Genotyping of bone marrow from a male patient with refractory cytopenia with multilineage dysplasia and ringed sideroblasts and an abnormal karyotype

Project description:Somatic genetic copy number analysis of bone marrow from a male patient with refractory cytopenia with multilineage dysplasia and ringed sideroblasts and an abnormal karyotype, 45,XY,der(5)t(5;14)(q14;?q24),dic(17;20)(p13;q12),dic(17;20)(p11.2;q12),-18,+22[6]/45,XY,der(5)t(5;14)(q14;?q24),dic(17;20)(20pter->20p11.2::17p1?1.2->17p1?3::20q12->20q10::20q10->20q12::17p11.2->17qter),dic(17;20)(p11.2;q11.2),-18,+22[cp2]/46,XY,der(5)t(5;14)(q14;?q24),der(17)(20pter->20p13::20q11.2->20q11.2::17p13->17qter),der(17)(20pter->20p11.2::20q11.2->20q11.2::17p13->17qter),-18, 20,+22,+r[9] (Case 6, MacKinnon et al 2007, Genes Chr Cancer 46:27-36)

2010-01-09 | E-MEXP-2275 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data